Definitive Healthcare (NASDAQ:DH) Shares Gap Up to $4.44

Definitive Healthcare Corp. (NASDAQ:DH) shares gapped up prior to trading on Tuesday . The stock had previously closed at $4.44, but opened at $4.65. Definitive Healthcare shares last traded at $4.70, with a volume of 26,577 shares trading hands.

Analyst Ratings Changes

A number of research analysts have weighed in on the company. JPMorgan Chase & Co. lowered Definitive Healthcare from a “neutral” rating to an “underweight” rating and reduced their price target for the stock from $7.00 to $5.00 in a research note on Wednesday, July 31st. Stifel Nicolaus reduced their target price on Definitive Healthcare from $9.50 to $7.50 and set a “buy” rating on the stock in a research report on Wednesday, July 31st. Deutsche Bank Aktiengesellschaft lowered their price target on Definitive Healthcare from $7.00 to $5.00 and set a “hold” rating for the company in a report on Friday, August 9th. Barclays cut their price objective on shares of Definitive Healthcare from $6.00 to $4.00 and set an “equal weight” rating on the stock in a report on Wednesday, August 7th. Finally, Morgan Stanley lowered their target price on shares of Definitive Healthcare from $9.00 to $5.00 and set an “equal weight” rating for the company in a report on Tuesday, August 6th. One analyst has rated the stock with a sell rating, seven have given a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $5.81.

Definitive Healthcare Price Performance

The company has a quick ratio of 2.40, a current ratio of 2.40 and a debt-to-equity ratio of 0.27. The company’s fifty day moving average is $4.65 and its 200 day moving average is $5.91. The stock has a market cap of $537.78 million, a PE ratio of -2.61, a price-to-earnings-growth ratio of 6.38 and a beta of 1.33.

Definitive Healthcare (NASDAQ:DH) last issued its earnings results on Monday, August 5th. The company reported $0.09 EPS for the quarter, meeting analysts’ consensus estimates of $0.09. Definitive Healthcare had a negative net margin of 156.65% and a positive return on equity of 0.98%. The business had revenue of $63.70 million for the quarter, compared to the consensus estimate of $63.19 million. During the same quarter last year, the firm posted $0.08 EPS. The business’s revenue for the quarter was up 4.4% compared to the same quarter last year. As a group, sell-side analysts anticipate that Definitive Healthcare Corp. will post 0.07 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Definitive Healthcare

Institutional investors and hedge funds have recently modified their holdings of the stock. Swiss National Bank lifted its position in shares of Definitive Healthcare by 3.6% during the fourth quarter. Swiss National Bank now owns 100,400 shares of the company’s stock worth $998,000 after purchasing an additional 3,500 shares in the last quarter. Norden Group LLC acquired a new position in Definitive Healthcare in the 1st quarter worth $83,000. Conestoga Capital Advisors LLC boosted its position in Definitive Healthcare by 1.3% in the 1st quarter. Conestoga Capital Advisors LLC now owns 5,595,627 shares of the company’s stock valued at $45,157,000 after buying an additional 74,490 shares during the last quarter. Principal Financial Group Inc. acquired a new stake in shares of Definitive Healthcare during the first quarter valued at about $290,000. Finally, Oppenheimer Asset Management Inc. increased its position in shares of Definitive Healthcare by 40.5% during the first quarter. Oppenheimer Asset Management Inc. now owns 49,393 shares of the company’s stock worth $399,000 after acquiring an additional 14,229 shares during the last quarter. Hedge funds and other institutional investors own 98.67% of the company’s stock.

About Definitive Healthcare

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.